nct_id: NCT06492616
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-07-09'
study_start_date: '2024-09-27'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Letrozole'
  - drug_name: 'Drug: Anastrozole'
  - drug_name: 'Drug: Exemestane'
  - drug_name: 'Drug: Elacestrant'
  - drug_name: 'Drug: Tamoxifen'
long_title: Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive,
  Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of
  Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
last_updated: '2025-08-27'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Stemline Therapeutics, Inc.
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 4220
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Key Inclusion Criteria:'
- "* Histopathologically or cytologically confirmed ER-positive (\u2265 10% by immunohistochemistry\
  \ \\[IHC\\]), HER2-negative \\[IHC = 0 or 1, or (IHC = 2 and in situ hybridization\
  \ \\[ISH\\]-negative)\\] on tumor biopsy or final surgical pathology specimen early\
  \ stage resected invasive breast cancer without evidence of recurrence or distant\
  \ metastases, per local laboratory, according to the American Society of Clinical\
  \ Oncology (ASCO)/College of American Pathologists (CAP) guidelines"
- '* Participants considered at high risk of recurrence at initial staging'
- '* Participants who have received at least 24 months but not more than 60 months
  of endocrine therapy (AIs or tamoxifen) with or without a CDK 4 and CKD 6 inhibitor
  (CDK4/6i)'
- '* Participants who received prior CDK4/6i or a poly adenosine diphosphate-ribose
  polymerase (PARP) inhibitor must have already completed or discontinued these treatments.'
- 'Exclude - Key Exclusion Criteria:'
- Exclude - * Participants with inflammatory breast cancer
- Exclude - * History of any prior (ipsilateral and/or contralateral) invasive breast
  cancer
- Exclude - * Participant with history of malignancy within 3 years of the date of
  randomization, except for adequately treated basal or squamous cell skin cancer,
  superficial bladder cancer or carcinoma in situ of the cervix
- Exclude - * Participants who have had more than a 6-month continuous interruption
  of prior SoC adjuvant endocrine therapy or who discontinued adjuvant endocrine therapy
  more than 6 months prior to randomization
- 'Exclude - Note: Other protocol defined Inclusion/Exclusion criteria may apply.'
short_title: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and
  Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Stemline Therapeutics, Inc.
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The primary goal of this study is to evaluate the effectiveness of elacestrant
  versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive
  (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with
  high risk of recurrence.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Elacestrant
      arm_internal_id: 0
      arm_description: Participants will receive 345 milligrams (mg) elacestrant once
        daily (QD) for 5 years
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Elacestrant'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Standard of Care (SoC) Endocrine Therapy
      arm_internal_id: 1
      arm_description: 'Participants will receive the SoC endocrine therapy that was
        used prior to randomization:


        * AI (anastrozole 1 mg QD, letrozole 2.5 mg QD, or exemestane 25 mg QD); or

        * Tamoxifen 20 mg QD'
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Anastrozole'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Letrozole'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Exemestane'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Tamoxifen'
        level_internal_id: 3
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Inflammatory Breast Cancer
        - clinical:
            oncotree_primary_diagnosis: Breast Ductal Carcinoma In Situ
        - clinical:
            oncotree_primary_diagnosis: Breast Neoplasm, NOS
        - clinical:
            oncotree_primary_diagnosis: Invasive Breast Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Breast Lobular Carcinoma In Situ
      - clinical:
          age_numerical: '>=18'
          her2_status: Negative
          er_status: Positive
          disease_status:
          - Early Stage
